Creabilis Announces Positive Phase IIa Results for TrkA Kinase Inhibitor CT327 in Psoriasis Vulgaris | wallstreet:online
Links shared publicly online about this topic.
- 450total visits
Creabilis Announces Positive Phase IIa Results for TrkA Kinase Inhibitor CT327 in Psoriasis Vulgaris | wallstreet:online
View full resource at wallstreet-online.de
Tags: Dermatology, Psoriasis, Biotech, Medical
Most Recently Shared on March 10, 2011 at 3:26 pm By:
Creabilis Announces Positive Phase IIa Results for TrkA Kinase Inhibitor CT327 in Psoriasis Vulgaris: LUXEMBOURG... http://bit.ly/eNcxld
Also Shared By:
Creabilis Announces Positive Phase IIa Results for TrkA Kinase Inhibitor CT327 in Psoriasis Vulgaris - Health News - redOrbit
redorbit.com — “LUXEMBOURG, March 10, 2011 /PRNewswire/ -- Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, today announced positive results from its Phase IIa study of its lead product CT327 in psoriasis vulgaris. CT327 is a novel topically applied TrkA kinase inhibitor developed using Creabilis' LSE (Low Systemic Exposure) technology.” View full resource at redorbit.com
Most Recently Shared on March 10, 2011 at 11:50 am By:
Creabilis Announces Positive Phase IIa Results for TrkA Kinase Inhibitor CT327 in Psoriasis Vulgaris: LUXEMBOURG... http://bit.ly/fon4Bh
Advertisement
PsoriasisTx.com
@PsoriasisTx
RT @psoriasis_ow: Phase IIa Results for TrkA Kinase Inhibitor CT327 in #Psoriasis Vulgaris: LUXEMBOURG... http://bit.ly/eNcxld
1 year ago...